DIREKT: Disarming The Intravascular Innate Immune Response To Improve Modalities For Chronic Kidney Disease Treatment
Funder
National Health and Medical Research Council
Funding Amount
$362,830.00
Summary
Dialysis is the mainstay treatment for patients with end-stage kidney disease while they await transplantation. However, the dialysis process causes inflammation in patients, affecting their health and longevity. This project aims to develop new bioreagents that can be applied to dialysis devices to reduce inflammation and thus improve patient outcomes. These bioreagents will also be used to modify donor kidneys so that they are protected from inflammation associated with transplantation.
The Missing Link: MGluR5 As A Therapeutic Target For Cognitive Decline In Dementia
Funder
National Health and Medical Research Council
Funding Amount
$563,622.00
Summary
Cognitive decline is a core feature of Alzheimer’s Disease (AD), yet there is no cure or treatment. Recent evidence suggests that a protein called mGluR5 could cause brain cells to lose function, leading to memory loss. This project will investigate whether disrupting mGluR5 function can improve cognition in mice with genetic AD. Memory will be assessed in mice using innovative touchscreen tests that closely mimic the tests used in humans.
Restoring Defective Protein Homeostasis In Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
Frontotemporal dementia (FTD) is associated with pathological accumulation and aggregation of toxic proteins in affected brain regions. This project will employ a novel high throughput drug screening platform technology, FTD patient-derived nerve cells and genetic mouse models to screen drugs to improve clearance of toxic proteins and nerve cell health. This approach should accelerate discovery of agents to potentially treat the underlying cause of FTD in an effort to slow disease progression.
L1 Retrotransposition: The Missing Link Between Genetics And Environmental Factors In Parkinson's Disease ?
Funder
National Health and Medical Research Council
Funding Amount
$604,644.00
Summary
The study proposed here focuses on understanding the role of specific mobile DNA sequences in the interaction between environmental and genetic risk factors causing Parkinson’s disease (PD) leading to dementia. The project proposes identification of mobile DNA induced mutations in post-mortem human PD patient brain samples. The significance and mechanisms of mobile DNA induced mutations will be then tested in a PD mouse model.
Discovery Of Novel Neurodegeneration Genes Via Next-generation Sequencing Technologies And High-throughput Cellular Assays
Funder
National Health and Medical Research Council
Funding Amount
$715,144.00
Summary
My research program aims to discover genes that are mutated in dementia, by identifying gene variants present in patients and absent in healthy people, and examining how these variants affect the function of cells. Identifying new dementia genes will reveal the biological processes that lead to brain cell death. Knowledge of these processes is crucial for the development of new treatments for the many people affected worldwide with dementia.
LIFECYCLE - Early Life Stressors And LifeCycle Health
Funder
National Health and Medical Research Council
Funding Amount
$453,811.00
Summary
Early in life is a period of time during which we can institute changes that can have long lasting benefits for asthma, obesity, diabetes mellitus and mental and cardiovascular health. The current project, LIFECYCLE is a cooperative project with a combined total of a quarter of a million participants, which will be the definitive study to determine, which early life events should be modified for improving health trajectories throughout life.
Towards Targeting The Endosome In Neurodegenerative Disease
Funder
National Health and Medical Research Council
Funding Amount
$601,959.00
Summary
Mutations and dysregulation of the SNX27-retromer protein platform are strongly linked to Alzheimer’s disease (AD) and Parkinson’s disease (PD). This research program will determine how SNX27-retromer interacts with key molecules associated with AD and PD, the outcomes of which be significantly improved understanding of how mutations in these proteins cause disease, and a necessary molecular framework for future therapeutic targeting.
BRAIN-MEND: Biological Resource Analysis To Identify New Mechanisms And Phenotypes In Neurodegenerative Diseases
Funder
National Health and Medical Research Council
Funding Amount
$861,866.00
Summary
Current classification of neurodegenerative diseases (ND) based on clinical phenotypes does not take into account underlying disease heterogeneity, or overlapping disease mechanisms, thus hindering therapy development. Segregation and re-classification of ND phenotypes is urgently needed. BRAIN-MEND will reclassify existing phenotypic classifications using using pathway and network analyses within and across complex NDs.
Longitudinal Transcriptome Profiles For People With Dementia
Funder
National Health and Medical Research Council
Funding Amount
$475,913.00
Summary
Over the past decade, less than half a percent of drugs trialled for Alzheimer Disease were found to be effective. This highlights the need for new drug targets. This Fellowship aims to study how genes express themselves over time, among people with very high risk of dementia (genetic form of Alzheimer Disease and Huntington Disease). By looking at gene expression in nerve tissue in the nose, fluid around the brain, and blood, I hope to better understand the disease mechanisms causing dementia.
Development Of Blood-based Biomarkers For The Early Detection Of Brain Amyloid And The Investigation Of The Natural History Of Alzheimer’s Disease.
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
To have a direct impact on the diagnosis and treatment of Alzheimer’s and other neurodegenerative diseases we need a detailed molecular understanding of the proteins that drive the disease. My laboratory develops and applies the most advanced analytical tools available to develop blood-based markers that can detect the development of Alzheimer’s disease before symptoms occur. This Fellowship will allow me to expand our understanding of the natural history of Alzheimer’s disease.